SCHEMBL1044213

SCHEMBL1044213

[N]ON

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7648923 0.71
SCHEMBL45002 0.67
Hydrogen Sulfide SCHEMBL7933936 0.62
SCHEMBL166599 0.61
SCHEMBL31268158 0.61
Hydrochloric Acid SCHEMBL28526767 0.61
Hydrochloric Acid SCHEMBL9863746 0.55
SCHEMBL29283229 0.55
SCHEMBL28824575 0.55
SCHEMBL10354529 0.55

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140155429-A1 Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Nicotine ENVIVO PHARMACEUTICALS, INC. (US) 2014-06-05 US claimed
EP-2725906-A1 METHODS OF TREATMENT OF LIMITED COGNITIVE IMPAIRMENT Envivo Pharmaceuticals, Inc. (US) 2014-05-07 EP claimed
EP-2706854-A1 TREATMENT OF COGNITIVE DISORDERS WITH CERTAIN ALPHA-7 NICOTINIC ACID RECEPTOR AGONISTS IN COMBINATION WITH NICOTINE Envivo Pharmaceuticals, Inc. (US) 2014-03-19 EP claimed
WO-2013006365-A1 METHODS OF TREATMENT OF LIMITED COGNITIVE IMPAIRMENT ENVIVO PHARMACEUTICALS, INC. (US) 2013-01-10 WO claimed
WO-2012154710-A1 TREATMENT OF COGNITIVE DISORDERS WITH CERTAIN ALPHA-7 NICOTINIC ACID RECEPTOR AGONISTS IN COMBINATION WITH NICOTINE ENVIVO PHARMACEUTICALS, INC. (US) 2012-11-15 WO claimed
EP-0854861-A1 OXYAMINO OXIME ETHERS, METHODS AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION, AND AGENTS CONTAINING THEM AND USED FOR CONTROLLING HARMFUL FUNGI AND PESTS BASF AKTIENGESELLSCHAFT (DE) 1998-07-29 EP claimed
WO-1997013747-A1 OXYAMINO OXIME ETHERS, METHODS AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION, AND AGENTS CONTAINING THEM AND USED FOR CONTROLLING HARMFUL FUNGI AND PESTS BASF AKTIENGESELLSCHAFT (DE) 1997-04-17 WO claimed
US-20260132404-A1 MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS ALNYLAM PHARMACEUTICALS, INC. (US) 2026-05-14 US disclosed
US-20250304613-A1 AMINOOXY CLICK CHEMISTRY (AOCC): A VERSATILE CONJUGATION APPROACH ALNYLAM PHARMACEUTICALS, INC. (US) 2025-10-02 US disclosed
EP-4561631-A2 MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS Alnylam Pharmaceuticals, Inc. (US) 2025-06-04 EP disclosed
EP-4367125-A1 AMINOOXY CLICK CHEMISTRY (AOCC): A VERSATILE BIOCONJUGATION APPROACH Alnylam Pharmaceuticals, Inc. (US) 2024-05-15 EP disclosed
WO-2024073709-A2 MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS ALNYLAM PHARMACEUTICALS, INC. (US) 2024-04-04 WO disclosed
WO-2023283434-A9 AMINOOXY CLICK CHEMISTRY (AOCC): A VERSATILE BIOCONJUGATION APPROACH ALNYLAM PHARMACEUTICALS, INC. (US) 2024-03-28 WO disclosed
US-20060046983-A1 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY 2006-03-02 US disclosed
WO-2006020082-A1 INHIBITORS OF HCV REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2006-02-23 WO disclosed
US-20050215577-A1 Tetrahydrocarbazoles and derivatives HOFFMANN-LA ROCHE INC. 2005-09-29 US disclosed
US-20040137334-A1 Volume hologram recording photosensitive composition, volume hologram recording photosensitive medium and volume hologram DAI NIPPON PRINTING CO., LTD. (JP) 2004-07-15 US disclosed
US-20030129385-A1 Photocurable resin composition, finely embossed pattern-forming sheet, finely embossed pattern transfer sheet, optical article, stamper and method of forming finely embossed pattern DAI NIPPON PRINTING CO., LTD. (JP) 2003-07-10 US disclosed
US-6316482-B1 FOR THERAPY AND PROPHYLAXIS OF HYPERTENSION, HEART FAILURE, RENAL INSUFFICIENCY, EDEMA, ASCITES, VASOPRESSIN PARASECRETION SYNDROME, HEPATOCIRRHOSIS, HYPONATREMIA, HYPOKALEMIA, DIABETIC, CIRCULATION DISORDER, CEREBROVASCULAR DISEASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-13 US disclosed
US-6207693-B1 Benzamide derivatives having a vasopressin antagonistic activity FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-03-27 US disclosed